<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01647789</url>
  </required_header>
  <id_info>
    <org_study_id>CCFG920X2101</org_study_id>
    <secondary_id>2012-001961-33</secondary_id>
    <nct_id>NCT01647789</nct_id>
  </id_info>
  <brief_title>A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer</brief_title>
  <official_title>A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and preliminary antitumor activity of CFG920, a new CYP17
      inhibitor in castration resistant prostate cancer patients who are abiraterone naive or
      abiraterone resistant.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of dose limiting toxicities (DLT)</measure>
    <time_frame>28 days (from the time of first dose)</time_frame>
    <description>Phase l; cycle = 28 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of patients with Prostate Specific Antigen (PSA) response</measure>
    <time_frame>&gt;= 12 weeks</time_frame>
    <description>Phase ll only</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events (AEs)</measure>
    <time_frame>18 months</time_frame>
    <description>Phase l, Phase ll</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>﻿PK parameters</measure>
    <time_frame>18 months</time_frame>
    <description>Phase l, Phase ll</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen (PSA) response (≥50% in PSA reduction)</measure>
    <time_frame>18 months</time_frame>
    <description>Phase l only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>baseline, until disease progression up to 6 months (6 cycle)</time_frame>
    <description>Phase ll only; cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events (SAEs)</measure>
    <time_frame>18 months</time_frame>
    <description>Phase l, Phase ll</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>up to 2 months (cycle 2)</time_frame>
    <description>Phase ll; cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response rate (ORR)</measure>
    <time_frame>up to 2 months (cycle 2)</time_frame>
    <description>Phase ll</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological Time to Progression (rTTP)</measure>
    <time_frame>baseline, until date of documented disease progression</time_frame>
    <description>Phase ll only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen (PSA) response (≥30% in the PSA reduction)</measure>
    <time_frame>18 months</time_frame>
    <description>Phase ll only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best PSA response at any time during the study</measure>
    <time_frame>18 months</time_frame>
    <description>Phase ll only</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of serum hormone levels</measure>
    <time_frame>18 months</time_frame>
    <description>Phase I, Phase II</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlate plasma exposure parameters of CFG920 and serum hormones</measure>
    <time_frame>18 months</time_frame>
    <description>Phase I, Phase II</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate moleculare profiles</measure>
    <time_frame>18 months</time_frame>
    <description>Phase I, Phase II</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>CFG920</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFG920</intervention_name>
    <arm_group_label>CFG920</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of castration resistant prostate cancer

          -  Documented metastases

          -  ECOG performance status 0 or 1

          -  Documented progression following the Prostate Cancer Working Group 2 guidelines

          -  Fresh or archived tumor sample

        Exclusion Criteria:

          -  Impaired cardiac function

          -  Uncontrolled hypertension despire appropriate medical therapy

          -  History of pituitary or adrendal dysfunction

          -  Chronic steriod therapy other than daily use of 10mg prednisone

          -  Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of oral CFG920

          -  Brain metastases that have not been adequately treated

          -  Malignant disease other than that being treated in this study

          -  Laboratory abnormalities as specified in the protocol Other protocol-defined
             inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco Dept of Oncology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research Center / UT Health Science Center InstituteForDrugDevelopment(2)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance Dept. of SCCA</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Univ Wisc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bouge</city>
        <zip>5004</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Singapore</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer, castration resistant,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

